Stephens restated their overweight rating on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $31.00 price objective on the stock.
NRIX has been the subject of several other reports. Jefferies Financial Group initiated coverage on Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 price target for the company. HC Wainwright increased their price objective on Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, June 18th. Oppenheimer boosted their target price on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, September 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Nurix Therapeutics in a research report on Monday. Finally, Robert W. Baird initiated coverage on shares of Nurix Therapeutics in a research report on Friday, September 6th. They issued an “outperform” rating and a $26.00 price objective for the company. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $28.71.
Check Out Our Latest Research Report on Nurix Therapeutics
Nurix Therapeutics Stock Performance
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last released its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The firm had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. On average, sell-side analysts anticipate that Nurix Therapeutics will post -2.95 earnings per share for the current fiscal year.
Insider Activity
In other news, CFO Houte Hans Van sold 2,490 shares of the business’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total transaction of $51,468.30. Following the completion of the sale, the chief financial officer now directly owns 54,479 shares of the company’s stock, valued at $1,126,080.93. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,490 shares of the company’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the completion of the sale, the chief financial officer now directly owns 54,479 shares of the company’s stock, valued at approximately $1,126,080.93. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Christine Ring sold 3,290 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $25.00, for a total transaction of $82,250.00. Following the completion of the sale, the insider now directly owns 24,592 shares of the company’s stock, valued at $614,800. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 63,105 shares of company stock worth $1,507,181. Company insiders own 7.20% of the company’s stock.
Institutional Trading of Nurix Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. Teachers Retirement System of The State of Kentucky bought a new position in shares of Nurix Therapeutics in the 2nd quarter worth $578,000. Driehaus Capital Management LLC bought a new position in shares of Nurix Therapeutics in the 2nd quarter worth $26,778,000. The Manufacturers Life Insurance Company increased its holdings in shares of Nurix Therapeutics by 25.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,942 shares of the company’s stock worth $479,000 after buying an additional 4,583 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Nurix Therapeutics by 60.2% in the 2nd quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock worth $12,514,000 after buying an additional 225,374 shares during the last quarter. Finally, Dark Forest Capital Management LP bought a new position in shares of Nurix Therapeutics in the 2nd quarter worth $201,000.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
- Five stocks we like better than Nurix Therapeutics
- How to Invest in Biotech Stocks
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What is a Death Cross in Stocks?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.